25 August 2010 – The Board of Directors of NeuroSearch A/S (NEUR) considered and adopted the company’s interim report for the period 1 January to 30 June 2010.The operating result for the period was a loss of DKK 168.0 million (a loss of DKK 204.1 million in the same period of 2009). The company’s capital resources totalled DKK 808.4 million at 30 June 2010 (DKK 488.9 at 30 June 2009), consisting primarily of highly liquid short-term bonds and guaranteed future payments from partners. Financial net income for the period positively affected net results by DKK 20.5 million.
Key business events and development in the second quarter of 2010 and the subsequent period:
Huntexil® (pridopidine) – Huntington’s disease...
[...]
Tesofensine – Obesity
– A new Phase III plan is in preparation and in this relation NeuroSearch is closely following the US regulatory authorities' evaluation of other drugs to treat obesity. A revised Phase III plan is expected to be ready for discussion with the US and the European regulatory authorities in the fourth quarter of 2010.
– NeuroSearch will continue the dialogue with potential partners with the aim of signing a licensing agreement before the initiation of Phase III... NeuroSearch's Press Release -
